MIDOSTAURIN Drug Patent Profile

When do Midostaurin patents expire, and what generic alternatives are available?

Midostaurin is a drug marketed by Dr Reddys, Lupin, and Teva Pharms. and is included in three NDAs.

The generic ingredient in MIDOSTAURIN is midostaurin. One supplier is listed for this compound. Additional details are available on the midostaurin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Midostaurin

A generic version of MIDOSTAURIN was approved as midostaurin by LUPIN on May 10^th, 2024.

Summary for MIDOSTAURIN

US Patents:	0
Applicants:	3
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MIDOSTAURIN

Paragraph IV (Patent) Challenges for MIDOSTAURIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYDAPT	Capsules	midostaurin	25 mg	207997	4	2021-04-28

US Patents and Regulatory Information for MIDOSTAURIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	MIDOSTAURIN	midostaurin	CAPSULE;ORAL	215921-001	Jun 28, 2024	AB	RX	No	No
Lupin	MIDOSTAURIN	midostaurin	CAPSULE;ORAL	216015-001	May 10, 2024	AB	RX	No	No
Teva Pharms	MIDOSTAURIN	midostaurin	CAPSULE;ORAL	216076-001	Apr 29, 2024		DISCN	No	No

Midostaurin (Rydapt) Investment Scenario and Patent-Funded Fundamentals: Exclusivity, Generic/Biosimilar Risk, Revenue Exposure, and Litigation Landscape

Last updated: July 16, 2026

Midostaurin’s U.S. franchise is dominated by Bay 11-7082’s first-launch competitive position in AML and aggressive systemic mastocytosis (ASM) alongside FDA approvals that support durable label breadth. The investment thesis hinges on (1) the end of regulatory exclusivity and patent term gradients in the U.S. and key ex-U.S. markets, (2) whether generic entrants can clear formulation/process and method-of-use IP, and (3) the magnitude of remaining use tied to continued guideline uptake versus survivorship shrinkage as newer agents expand in AML and mastocytosis care. On the IP side, exclusivity and composition/method-of-use coverage create a staggered entry risk profile rather than an all-at-once generic wall break.

How does midostaurin make money: what are the revenue drivers and risk factors?

Midostaurin’s commercial base is multi-indication and treatment-pattern dependent. The two anchor populations are:

• Newly diagnosed FLT3-mutated AML (in combination with standard cytarabine/daunorubicin induction and cytarabine consolidation)
  Revenue sensitivity: adoption rate versus FLT3 inhibitor competitor mix; changes in induction/consolidation standards; sequencing after relapse.
• Advanced systemic mastocytosis (ASM, systemic mastocytosis with associated hematologic neoplasm, and mast cell leukemia)
  Revenue sensitivity: comparative tolerability and efficacy in real-world practice; duration of therapy; payer coverage restrictions.

Fundamental drivers

• Guideline anchoring for FLT3-mutated AML combination therapy supports baseline demand.
• Orphan-like dynamics in advanced mastocytosis support premium pricing stability longer than broad oncology agents, assuming patent and payer coverage hold.
• Formulary stickiness when treatment teams maintain established regimens, especially where monitoring and adverse event management pathways are known.

Primary downside vectors

• Competition pressure in FLT3-mutated AML from agents with better efficacy-to-toxicity profiles and/or more convenient schedules.
• Loss of label share if standard-of-care shifts away from midostaurin combination sequences.
• Exclusivity erosion that accelerates cost pressure via generics once patent barriers clear.

What patents protect midostaurin in the US and how strong is the estate?

Midostaurin’s protection typically concentrates in three buckets:

1. Composition of matter for midostaurin (and close analogs)
2. Formulation patents for oral dosage and manufacturing-relevant properties
3. Method-of-use patents tied to FLT3-mutated AML regimens and advanced mastocytosis treatment

A practical investment read-through: even if composition barriers are near term, secondary patents can keep generic entry timelines uneven by forcing Paragraph IV carve-outs or triggering litigation around specific claims (formulation/process or labeled regimens).

Estate strength indicators for investors

• Claim diversity: more independent claim types increase entry friction for first Paragraph IV filers.
• Geographic redundancy: overlapping EP/WO family coverage reduces “weak-link” country bets.
• Litigation history: active enforcement signals higher probability of settlement rather than default generic launches.

When does midostaurin lose exclusivity: what are the U.S. regulatory exclusivity and patent expiration timing?

Midostaurin’s “when” question should be decomposed into:

• Regulatory exclusivity: granted under FDA exclusivity rules (compound and approval pathway dependent).
• Patent expiration: composition, method-of-use, and formulation claims with different end dates.
• Practical loss of exclusivity: first generic availability post-eligibility and post-litigation.

Investment framing:

• The earliest generic entry window is the first date a competitor can market without infringement risk for the specific product version they plan to sell.
• The earliest settlement-driven “at-risk-to-foreclose” window is when parties agree to a delay tied to an IP milestone.

What is the Orange Book status of Rydapt (midostaurin) and what does it imply for generic entry?

The FDA’s Orange Book listings function as a map of marketed-product IP for the Orange Book drug product and strength. The key investment-use items are:

• List of U.S. patents and their expiration dates
• Patent coverage type (composition, method of use, formulation)
• Any pediatric exclusivity extensions tied to granted pediatric requirements

A clean entry is unlikely unless a filer can:

• avoid infringement of at least one listed patent set by filing to non-infringement/invalidity for the correct claims, and
• prevail in litigation or win at settlement.

The higher the count of listed patents expiring on different dates, the more likely the market experiences delayed, staggered generics rather than a single price shock.

What generic entry risks exist for midostaurin: which Paragraph IV challenges matter?

In mid-to-large oncology portfolios, the first Paragraph IV filer tends to be a bellwether for:

• whether patent claims are considered enforceable by courts and whether litigants believe claims are weak,
• whether settlement yields “launch calendars” that anchor the next 1 to 2 filers.

Investment-relevant Paragraph IV signals

• Number of ANDA filings referencing Rydapt
• Which patents are challenged (composition only versus formulation/method-of-use)
• Litigation posture at key procedural milestones (motions, Markman, settlement terms)

Generic entry risk rises when:

• The most defensible patents are close to expiration, and
• Challenged claims are narrow enough for a generic product to design around.

Generic entry risk falls when:

• Filers challenge broad independent claims that historically sustain injunction leverage, and
• secondary patents (formulation/process or method-of-use) remain unexpired.

What patent litigation affects midostaurin: where are the cases and what outcomes drive timing?

For midostaurin, litigation typically affects:

• ANDA 30-month stays (U.S.)
• Injunction risk against launch
• Settlement design (delayed entry dates, carve-outs, shared confidentiality)

Investment interpretation

• If litigation results in early defeats for generic plaintiffs or high settlement payouts, the market experiences a longer protected window.
• If cases settle with a meaningful “carve-out date,” investors can map a specific launch calendar for follow-on ANDAs.

How do midostaurin competitors change the investment outlook in FLT3-mutated AML?

The FLT3-mutated AML standard is increasingly competitive. Midostaurin’s investment sensitivity includes:

• share drift if later-line FLT3 inhibitors or next-generation agents improve outcomes or reduce toxicity,
• sequencing changes where midostaurin is displaced by alternative FLT3 inhibitors,
• center-of-excellence prescribing patterns that can shift adoption dynamics before formal guideline updates.

Competitive pressure impacts fundamentals even if IP holds, because oncology pricing and reimbursement can soften.

How does midostaurin compare with other FLT3 inhibitors on commercial sustainability?

A direct comparison for investors should use three axes:

1. Label breadth and combination positioning: durability depends on whether midostaurin keeps a core place across induction and consolidation.
2. Safety and tolerability profile: affects continuation rates and payer authorization patterns.
3. Patent runway: if peers have earlier generic exposures, market share may reallocate toward the longer protected agent.

Midostaurin’s differentiator in investment terms is its combination label and its established presence in practice, with risk tied to whether newer FLT3 inhibitors cannibalize standard combination use.

What formulations are protected by midostaurin patents and does that block generics?

Formulation patents determine whether a generic can launch on a bioequivalence basis alone or whether it must address:

• dissolution profile and particle size attributes,
• excipient composition and manufacturing process constraints,
• oral dosage form-specific characteristics.

If formulation patents remain unexpired, ANDA genericers may be forced into:

• claim carve-outs that map to alternative formulations (often not practical),
• or litigation targeting the formulation claims.

For investors, formulation claim breadth is a strong driver of whether the first generic truly clears the market.

Are method-of-use patents a barrier for midostaurin generics in AML and mastocytosis?

Method-of-use patents are often the largest practical barrier in oncology and niche hematology:

• They can preserve the brand’s commercial moat even if composition coverage is weaker.
• They create a risk that a generic launch is technically possible but commercially unattractive unless the label is narrow enough to avoid infringement.

For midostaurin, if method-of-use claims map to:

• FLT3-mutated AML in combination regimen steps, and
• advanced systemic mastocytosis disease-state treatment,

then generic launch timing depends on whether ANDA labeling is carved to non-infringing use or whether the method claims are invalidated.

What biologics or biosimilar risk exists for midostaurin?

Midostaurin is a small-molecule oral drug. Biosimilar risk does not apply. The investment risk is almost entirely generic small-molecule competition through ANDAs.

What manufacturing and IP barriers could delay generic midostaurin?

Even if patent clearance is achieved, the practical barriers include:

• stability of the midostaurin API and oral dosage formulation,
• process validation reproducibility,
• dissolution and bioequivalence consistency at commercial scale.

If formulation/process claims remain tied to validated manufacturing techniques, genericers face more than a legal barrier. That can translate into later launch dates even after a legal “right to market.”

Where is midostaurin protected outside the U.S. and how does geography change the payoff?

Investment payoffs depend on:

• EP/WO family strength for composition and formulations,
• enforcement in key markets (EU, UK, Canada, Japan, major emerging markets),
• local patent term adjustments and patent linkage practices.

A global generic entry often arrives in waves:

• first in the U.S. (linkage and litigation),
• then EU/UK based on similar patent expiry and local enforcement.

For an investor, the question is whether a U.S. generic entry triggers price pressure globally or stays local to the U.S. via distribution and reimbursement dynamics.

What licensing deals or settlements could shape midostaurin’s protected period?

Settlement agreements with ANDA filers typically:

• specify launch dates,
• allow limited sales by the generic under defined conditions,
• include restrictions on design changes or future filings.

For investment modeling, the key input is whether settlements:

• create a single “end date” for all generics, or
• stagger entry with multiple plaintiffs and different settlement calendars.

The more distinct the patent set challenged by each ANDA, the more likely settlements differ.

How strong is the midostaurin patent-funded moat versus generic timelines: an entry-risk framework

A practical entry-risk framework:

• Step 1: Identify earliest patent expiration among Orange Book-listed patents relevant to composition, method-of-use, and formulation.
• Step 2: Map which claims are likely challenged in Paragraph IV filings.
• Step 3: Model litigation outcomes into U.S. stay calendars and settlement-driven launch dates.
• Step 4: Adjust for competitive displacement risk in AML and mastocytosis.

If composition patents end first but method/formulation barriers remain, the generic may face label carve-outs or slower commercialization. If composition and method claims expire within a tight window, the market can experience a sharper price impact.

Investment scenario: base case, bull case, and bear case

Base case

• Patent estate maintains market protection into the period where at least one key method/formulation barrier remains.
• Generic entry is delayed or arrives first in a limited manner.
• Midostaurin keeps label-driven demand in FLT3-mutated AML combination use and advanced mastocytosis.

Bull case

• Litigation or claim scope sustains injunction leverage longer than market expects.
• Patent expirations are pushed out by extensions or settlements.
• Competition does not fully displace combination use, sustaining volume and reimbursement.

Bear case

• Multiple core patents reach expiration and are neutralized via favorable litigation outcomes.
• ANDA filers converge on entry timing, leading to price compression.
• AML standard-of-care shifts reduce midostaurin combination utilization faster than the market can reprice via contracts.

Key Takeaways

• Midostaurin’s investment fundamentals are tied to multi-indication durability (FLT3-mutated AML combination and advanced systemic mastocytosis) and to how method-of-use and formulation patents constrain generic labeling and launch economics.
• Generic risk is primarily ANDAs against Orange Book-listed U.S. patents; biosimilar risk does not apply.
• The practical “exclusivity end” is defined less by any single patent and more by the staggering of composition, method-of-use, and formulation barriers plus litigation and settlement calendars.
• Competitive displacement in FLT3-mutated AML remains the largest non-IP driver of long-term revenue trajectory.

FAQs

1) What patents are most likely to delay generic midostaurin in the U.S.?
Method-of-use and formulation patents listed in the Orange Book tend to delay because they constrain label carve-outs and require specific design-around choices.

2) Does generic midostaurin need to match the branded formulation to launch?
If formulation patents remain listed, generics may need to pursue claim-safe product designs or litigate formulation claim scope, even if bioequivalence is otherwise achievable.

3) How does midostaurin’s AML combination use affect generic labeling risk?
Combination regimen method claims can make label carve-outs difficult, reducing commercial attractiveness of an early launch.

4) What settlement dynamics typically define the timing of midostaurin generic launches?
Settlement terms usually define a launch date tied to one or more contested patents and can differ by ANDA filer based on what claims each challenges.

5) Is the investment case for midostaurin sensitive to global generic entry after U.S. launch?
Yes, because global pricing pressure depends on patent expiry calendars and reimbursement/distribution patterns across major markets following U.S. launch.

References

No sources were provided in the prompt to cite.